AprilBio Co Ltd
KOSDAQ:397030
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Topcon Corp
TSE:7732
|
JP |
|
G
|
Guangzhou Newlife New Material Co Ltd
SZSE:301323
|
CN |
|
H
|
Heeton Holdings Ltd
SGX:5DP
|
SG |
AprilBio Co Ltd
Research & Development
AprilBio Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
AprilBio Co Ltd
KOSDAQ:397030
|
Research & Development
-₩4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Research & Development
-₩208B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-14%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Research & Development
-₩69.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Research & Development
-₩17.9B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Research & Development
-₩28.4B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-31%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Research & Development
-₩93B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
AprilBio Co Ltd
Glance View
AprilBio Co Ltd is a Korea-based company primarily engaged in the biological drug development business. The Company is primarily engaged in the bio-innovative new drug research and development (R&D) business such as antibody therapeutics and long-acting recombinant protein pharmaceuticals.
See Also
What is AprilBio Co Ltd's Research & Development?
Research & Development
-4B
KRW
Based on the financial report for Dec 31, 2025, AprilBio Co Ltd's Research & Development amounts to -4B KRW.
What is AprilBio Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
10%
Over the last year, the Research & Development growth was -25%. The average annual Research & Development growth rates for AprilBio Co Ltd have been 17% over the past three years , 10% over the past five years .
